Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

545
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
545
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

405
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
405
Cancer Therapies02:49

Cancer Therapies

7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Utility of Mechanical Echocardiographic Dispersion to Assess Left Ventricular Function and Ischemia or Infarction Detected by Gated 99M-Tc Sestamibi-SPECT.

Echocardiography (Mount Kisco, N.Y.)·2026
Same author

Evolving Patterns of Prevalence and Management of Hypertension Phenotypes in Mexico: A 2-Decade Analysis of Nationally Representative Surveys.

Hypertension (Dallas, Tex. : 1979)·2026
Same author

Prospective Study on the Evaluation of Echocardiographic Parameters as Predictors of a Positive Response to Cardiac Resynchronization Therapy in a Tertiary Care Hospital in Mexico.

Journal of clinical medicine·2026
Same author

Immune checkpoint inhibitor-induced myocarditis: a comprehensive review with clinical case insights.

Archivos peruanos de cardiologia y cirugia cardiovascular·2025
Same author

Cardiac Insights in Takayasu's Arteritis: Echocardiographic Differences in Active Takayasu Arteritis.

Echocardiography (Mount Kisco, N.Y.)·2025
Same author

Mid-ventricular hypertrophic cardiomyopathy with apical aneurysm: a multimodality imaging case report.

Archivos peruanos de cardiologia y cirugia cardiovascular·2025

Related Experiment Video

Updated: Jun 15, 2025

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

11.6K

Cancer Therapy-Related Cardiac Dysfunction: Strategies for Enhancing Cardiac Recovery.

Pavel Martinez-Dominguez1,2, Maria Jose Santa Ana-Bayona1, Enrique C Guerra1,3

  • 1National Institute of Cardiology Ignacio Chavez, Mexico City, Mexico.

Methodist Debakey Cardiovascular Journal
|August 26, 2024
PubMed
Summary

Cancer therapy-related cardiac dysfunction (CTRCD) affects 10% of patients, presenting challenges in cancer survivorship. Early detection and comprehensive management are key to improving cardiac recovery and patient outcomes.

Keywords:
cardiac dysfunctioncardiac recoverycardio-oncologycardiotoxicity

More Related Videos

Author Spotlight: Enhancing Coronary Artery Revascularization
05:25

Author Spotlight: Enhancing Coronary Artery Revascularization

Published on: September 15, 2023

664
Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy
11:38

Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy

Published on: July 3, 2014

46.7K

Related Experiment Videos

Last Updated: Jun 15, 2025

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

11.6K
Author Spotlight: Enhancing Coronary Artery Revascularization
05:25

Author Spotlight: Enhancing Coronary Artery Revascularization

Published on: September 15, 2023

664
Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy
11:38

Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy

Published on: July 3, 2014

46.7K

Area of Science:

  • Cardiology
  • Oncology
  • Pharmacology

Background:

  • Chemotherapy significantly improves cancer survival rates.
  • Cancer therapy-related cardiac dysfunction (CTRCD) affects approximately 10% of patients, posing a major challenge.
  • CTRCD can manifest asymptomatically or as heart failure.

Purpose of the Study:

  • To summarize current strategies for managing cardiotoxicity in cancer patients.
  • To highlight the importance of early detection and intervention for CTRCD.

Main Methods:

  • Review of multimodality imaging techniques, focusing on echocardiography for cardiac function monitoring.
  • Discussion of established and emerging biomarkers for CTRCD assessment, including troponin and B-type natriuretic peptide.
  • Overview of pharmacological interventions and cardiac rehabilitation programs for cardiotoxicity prevention and management.

Main Results:

  • Multimodality imaging, especially echocardiography, is crucial for monitoring cardiac function in patients undergoing chemotherapy.
  • Biomarkers like troponin and B-type natriuretic peptide aid in assessing CTRCD.
  • Pharmacological agents (dexrazoxane, ACE inhibitors, statins) and cardiac rehabilitation are vital for mitigating cardiotoxicity.

Conclusions:

  • A comprehensive, multidisciplinary approach is essential for managing CTRCD.
  • Early identification and intervention strategies improve cardiac recovery and overall patient outcomes in cancer survivors.